NASDAQ:PCRXPacira Biosciences Stock Price, Forecast & News

Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PCRX stock has increased by 64.8% and is now trading at $58.00. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences.

Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Pacira Biosciences.

Pacira Biosciences Inc (NASDAQ:PCRX) issued its quarterly earnings results on Thursday, May, 7th. The company reported $0.53 EPS for the quarter, topping the Zacks' consensus estimate of $0.30 by $0.23. The business had revenue of $105.68 million for the quarter, compared to analyst estimates of $101.64 million. Pacira Biosciences had a negative net margin of 0.02% and a positive return on equity of 13.89%. The company's revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.22 earnings per share. View Pacira Biosciences' earnings history.

Pacira Biosciences issued an update on its second quarter 2020 After-Hours earnings guidance on Monday, July, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $75.5-75.5 million, compared to the consensus revenue estimate of $57.81 million.

15 analysts have issued 1 year price objectives for Pacira Biosciences' shares. Their forecasts range from $41.00 to $85.00. On average, they expect Pacira Biosciences' share price to reach $59.14 in the next twelve months. This suggests a possible upside of 2.0% from the stock's current price. View analysts' price targets for Pacira Biosciences.

News stories about PCRX stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pacira Biosciences earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about Pacira Biosciences.

Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Bausch Health Companies (BHC), Exelixis (EXEL), Micron Technology (MU), Incyte (INCY) and Neurocrine Biosciences (NBIX).

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (0.33%), State of Alaska Department of Revenue (0.09%), Toth Financial Advisory Corp (0.03%) and Envestnet Asset Management Inc. (0.01%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences.

PCRX stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Toth Financial Advisory Corp, Envestnet Asset Management Inc., and State of Alaska Department of Revenue. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PCRX stock can currently be purchased for approximately $58.00.

Pacira Biosciences has a market capitalization of $2.44 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.

The official website for Pacira Biosciences is www.pacira.com.

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]